Charles A. Sanders

This profile gathers the share dealings of Charles A. Sanders across 7 companies, led by Vertex Pharmaceuticals INC / MA, Genentech Inc and Icagen, Inc. We count 87 filings; the first trade dates from 5 May 2006 and the latest from 29 February 2016.

On the open market, the record shows 5 purchases worth €71k and 45 sales worth €2.0M. Netting one side against the other leaves €1.9M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 7 share grants and 26 option exercises.

In size, the median ticket on the buying side is €8,213. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -32.9%. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 1 March 2016: a share grant of €8,008, in Biocryst Pharmaceuticals Inc. The last purchase on record was published on 15 March 2012, which is 5,335 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.